Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (251-260 of 566) with videos related to

Pageof 57
Sort By:
Blood|August 24, 2011
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneShaji K Kumar, Hajime Uno, Susanna J Jacobus, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Cancer Research|February 7, 2002
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group studyRafael Fonseca, David Harrington, Martin M Oken, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
British Journal of Haematology|May 26, 2012
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myelomaAlexandra J Greenberg, S Vincent Rajkumar, Dirk R Larson, et al.
Leukemia Research|March 21, 2016
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myelomaWilson I Gonsalves, Michael M Timm, S Vincent Rajkumar, et al.
Lancet (London, England)|May 18, 2010
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyAngela Dispenzieri, Jerry A Katzmann, Robert A Kyle, et al.
Blood Cancer Journal|May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Blood|November 29, 2002
POEMS syndrome: definitions and long-term outcomeAngela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Blood Cancer Journal|March 7, 2019
Two types of amyloidosis presenting in a single patient: a case seriesM Hasib Sidiqi, Ellen D McPhail, Jason D Theis, et al.
Pageof 57

Showing results (251-260 of 566) with videos related to

Sort By:
Pageof 57
Blood|August 24, 2011
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneShaji K Kumar, Hajime Uno, Susanna J Jacobus, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Cancer Research|February 7, 2002
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group studyRafael Fonseca, David Harrington, Martin M Oken, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
British Journal of Haematology|May 26, 2012
Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myelomaAlexandra J Greenberg, S Vincent Rajkumar, Dirk R Larson, et al.
Leukemia Research|March 21, 2016
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myelomaWilson I Gonsalves, Michael M Timm, S Vincent Rajkumar, et al.
Lancet (London, England)|May 18, 2010
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyAngela Dispenzieri, Jerry A Katzmann, Robert A Kyle, et al.
Blood Cancer Journal|May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Blood|November 29, 2002
POEMS syndrome: definitions and long-term outcomeAngela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Blood Cancer Journal|March 7, 2019
Two types of amyloidosis presenting in a single patient: a case seriesM Hasib Sidiqi, Ellen D McPhail, Jason D Theis, et al.
Pageof 57